Diamond Medino Capital

Diamond Medino is a clinical-stage Japanese biotechnology company specializing in the development of regenerative medicine therapies for central nervous system disorders. The company's core technology utilizes allogeneic bone marrow-derived mesenchymal stem cells (MSCs) to facilitate tissue repair and functional recovery in patients with severe injuries. Its lead product candidate, DMD-001, is currently being evaluated in Phase 2 clinical trials for the treatment of acute spinal cord injury. Diamond Medino aims to address significant unmet medical needs in neurology by providing standardized, off-the-shelf cell therapy products that do not require patient-specific harvesting. The company is headquartered in Tokyo and maintains strong collaborative ties with leading Japanese academic institutions for its research and development activities.